Koss Olinger Consulting LLC Has $259,000 Holdings in Thermo Fisher Scientific Inc. $TMO

Koss Olinger Consulting LLC lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 639 shares of the medical research company’s stock after selling 23 shares during the quarter. Koss Olinger Consulting LLC’s holdings in Thermo Fisher Scientific were worth $259,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also bought and sold shares of TMO. Nuveen LLC acquired a new stake in Thermo Fisher Scientific in the 1st quarter valued at $532,360,000. EdgePoint Investment Group Inc. acquired a new stake in Thermo Fisher Scientific in the 1st quarter valued at $172,139,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Thermo Fisher Scientific by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock valued at $1,368,859,000 after buying an additional 329,974 shares in the last quarter. Auto Owners Insurance Co boosted its stake in Thermo Fisher Scientific by 6,773.5% in the 1st quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company’s stock valued at $143,309,000 after buying an additional 283,810 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its stake in Thermo Fisher Scientific by 18.3% in the 1st quarter. Alliancebernstein L.P. now owns 1,766,067 shares of the medical research company’s stock valued at $878,795,000 after buying an additional 272,747 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on TMO. Barclays boosted their price objective on Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. HSBC reissued a “hold” rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Leerink Partners boosted their price objective on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 22nd. TD Cowen boosted their price objective on Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Finally, William Blair initiated coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an “outperform” rating on the stock. Nineteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $595.75.

Thermo Fisher Scientific Trading Down 1.4%

TMO stock opened at $564.49 on Tuesday. The company has a market cap of $213.16 billion, a P/E ratio of 32.61, a PEG ratio of 3.35 and a beta of 0.77. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The business has a fifty day moving average of $505.57 and a 200-day moving average of $454.34.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The company had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Insider Transactions at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of the company’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 400 shares of the company’s stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the sale, the chief executive officer owned 113,762 shares of the company’s stock, valued at $56,937,881. This represents a 0.35% decrease in their position. The disclosure for this sale can be found here. Insiders sold 29,666 shares of company stock valued at $13,990,971 in the last quarter. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.